This is a phase 3, multicenter, randomized, placebo-controlled, double- blinded clinical trial investigating the efficacy and safety of maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg) administered once weekly (QW) subcutaneously compared with placebo for body weight management, in participants who have obesity, or overweight with at least 1 obesity-related complication (excluding type 2 diabetes), and with at least 5% weight reduction following a 12-week intensive lifestyle intervention lead-in
Results from the landmark SELECT trial showed that weekly semaglutide lowered the risk of heart attack, stroke, or cardiovascular death by 20 percent in adults with overweight or obesity and established cardiovascular disease
Prior to treatment, we will take a careful medical history and conduct a consultation to minimise any potential risks and ensure that IV drip therapy is suitable for you
Combined, this multi-target action allows retatrutide to operate on various aspects of the metabolic system simultaneously
It may pose a different sort of hurdle, though, and that's the taste
Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized phase II/III trials
